

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3306332

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ENZON PHARMACEUTICALS, INC.		10/24/2013
RECEIVING PARTY DATA		
Name:	SANTARIS PHARMA A/S	
Street Address:	FREMTIDSVEJ 3	
City:	HERSHOLM	
State/Country:	DENMARK	
Postal Code:	DK2970	
PROPERTY NUMBERS Total: 5		
Property Type	Number	
Patent Number:	7737264	
Patent Number:	7846911	
Patent Number:	8207140	
Patent Number:	8357670	
Application Number:	13725540	
CORRESPONDENCE DATA		
Fax Number:	(801)578-6999	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	8015786978	
Email:	loren.hulse@stoel.com	
Correspondent Name:	LOREN R. HULSE	
Address Line 1:	201 SOUTH MAIN	
Address Line 2:	SUITE 1100	
Address Line 4:	SALT LAKE CITY, UTAH 84111	
ATTORNEY DOCKET NUMBER:	48188/5101,5102,5103,5104	
NAME OF SUBMITTER:	LOREN R. HULSE	
SIGNATURE:	/Loren R. Hulse/	
DATE SIGNED:	04/10/2015	
Total Attachments: 7		

source=Assignment 5100 Family#page1.tif
source=Assignment 5100 Family#page2.tif
source=Assignment 5100 Family#page3.tif
source=Assignment 5100 Family#page4.tif
source=Assignment 5100 Family#page5.tif
source=Assignment 5100 Family#page6.tif
source=Assignment 5100 Family#page7.tif

Schedule 6B

Form of Patent Assignment

ASSIGNMENT OF PATENT RIGHTS

This ASSIGNMENT OF PATENT RIGHTS (this "Assignment"), dated 10/24, 2013 (the "Effective Date"), is entered into by ENZON PHARMACEUTICALS, INC., a Delaware corporation ("Assignor"), for the benefit of SANTARIS PHARMA A/S, a corporation organized under the laws of Denmark (the "Assignee").

WHEREAS, Assignor agreed to assign, and the Assignee agreed to acquire, all of Assignor's right, title and interest, as of the Effective Date, in, to and under the issued patents and patent applications set forth on Schedule A.

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, all of Assignor's right, title and interest, as of the Effective Date, in, to and under the issued patents set forth on Schedule A and any reissues, reexaminations, and extensions thereof, and the patent applications set forth on Schedule A and all patents of the United States which may be granted thereon, and all divisions, renewals, continuations, and substitute applications thereof, and all patents worldwide that may be granted thereon, and all reissues, reexaminations, and extensions thereof, together with the right to file such applications and the right to claim for the same the priority rights derived from such patent application under the patent laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, each of the foregoing including, to the extent applicable, the right to seek damages and/or injunctive relief in the event of infringement of any such issued patent, with the right to sue for and receive the same for Assignee's own account and use, and, to the extent set forth above, for the use and on behalf of its successors and assigns.

ASSIGNOR HEREBY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this Assignment, and hereby grants the attorney of record the power to insert on this Assignment any further identification of the issued patents and the patent applications set forth on Schedule A that is necessary under the rules of the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States, for recordation of this Assignment, and agrees, without further consideration, at Assignee's expense, to execute and deliver such other documents that Assignee, its successors and/or assigns may reasonably request that are necessary under the rules of the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States, for recordation of this Assignment; provided that Assignee

CONFIDENTIAL
Execution Version

shall be solely responsible for performing all activities in connection with recordation of this Assignment with the United States Patent and Trademark Office, and the patent office of any country or countries foreign to the United States.

[Signatures Appear on the Following Page]

CONFIDENTIAL
Execution Version

IN WITNESS WHEREOF, Assignor has caused this Assignment to be to be executed by its duly authorized representatives effective as of the Effective Date.

[24 October, 2013]

By: [Signature]

STATE OF NEW JERSEY

COUNTY OF [Somerset]

On [October 24], before me, Charmene Davis-
personally appeared Andrew Rackear, personally known
to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the
same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on
the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the
instrument.

WITNESS my hand and official seal.

Signature C Davis-Lay (Seal)

My Commission Expires: July 23, 2017

Schedule A

LNA Compound Patents

HIF1- α mRNA antagonist
Santaris Ref. 1014

United States

7,737,264

7,846,911

8,207,140

8,357,670

13/725,540







